A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Association between post-COVID-19 neuropsychiatric symptoms and persistent glial activation in the limbic system: a TSPO PET study;




TekijätTuomaala, Joel; Saraste, Maija; Smith, Emma; Kuusi, Matilda; Westerberg, Elisabet; Honkonen, Eveliina; Kargar, Rahim; Laaksonen, Sini; Lehto, Jussi; Luoma, Amelie; Matilainen, Markus; Misin, Olavi; Atosuo, Janne; Kanerva, Mari; Liira, Helena; Laakso, Sini; Posharina, Tatiana; Saunavaara, Virva; Wahlroos, Saara; Rajander, Johan; Airas, Laura

KustantajaSpringer Science and Business Media LLC

Julkaisuvuosi2026

Lehti: Journal of Neurology

Artikkelin numero298

Vuosikerta273

ISSN0340-5354

eISSN1432-1459

DOIhttps://doi.org/10.1007/s00415-026-13842-w

Julkaisun avoimuus kirjaamishetkelläAvoimesti saatavilla

Julkaisukanavan avoimuus Osittain avoin julkaisukanava

Verkko-osoitehttps://doi.org/10.1007/s00415-026-13842-w

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/523815324

Rinnakkaistallenteen lisenssiCC BY

Rinnakkaistallennetun julkaisun versioKustantajan versio


Tiivistelmä

Background: A subset of individuals experience prolonged neurological and psychiatric symptoms following SARS-CoV-2 infection, a condition referred to as long COVID (LC). Limited evidence implicates ongoing neuroinflammatory processes as a driver of LC. This study investigates neuroinflammation in LC using translocator protein positron emission tomography (TSPO PET).

Methods: 14 LC, 11 healthy control (HC) and 13 multiple sclerosis (MS) participants were included in the study. They underwent [11C]PK11195 TSPO PET and 3T magnetic resonance imaging (MRI) to evaluate glial activation, white matter (WM) pathology and brain volumetrics. Serum neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) were measured as markers of neuronal and glial damage. LC participants completed neurological examinations and mental health assessments.

Results: TSPO availability, measured as distribution volume ratio (DVR), was not elevated in LC compared to HCs but was significantly lower in LC compared to MS (WM DVR 1.03 vs. 1.06; p = 0.007). Individuals imaged within 16 months of SARS-CoV-2 infection showed higher WM DVR compared to those with a longer disease duration (1.05 vs. 1.02; p = 0.04). Moreover, lower quality of life was associated with higher DVRs in the hippocampus, amygdala and thalamus (ρ = - 0.83- - 0.70), and depression and anxiety correlated positively with DVRs in the hippocampus and amygdala (ρ = 0.75-0.97).

Conclusions: LC TSPO availability did not differ from HCs in any studied brain area. However, lower WM TSPO availability in individuals with longer LC duration suggests COVID-19-associated neuroinflammation may subside with time, while the association between limbic TSPO availability and LC severity may imply a role for limbic activity in LC symptomology.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Julkaisussa olevat rahoitustiedot
Open Access funding provided by University of Turku (including Turku University Central Hospital). This work was funded by the Research Council of Finland grant for a clinical researcher (decision number: 330902), Sigrid Juselius Foundation (decision number N/A), Finnish MS Foundation (decision number N/A), Suomen lääketieteen Säätiö (decision number N/A), the InFLAMES Flagship Programme of the Academy of Finland (decision numbers: 374291, 337530, 357910 and 358823), and the European Union’s Horizon Europe research and innovation programme (grant agreement No 101057553).


Last updated on